TRIM22 Colocalizes with Centrosomes Independently of Cell Cycle Phase

Strategic Insights -

Researchers from Lund, Sweden have made a significant discovery regarding the human IFN-inducible p53 target gene TRIM22. This study, published in Experimental Cell Research, reveals that TRIM22, a member of the TRIM protein family, is localized to both the nucleus and cytosol in primary human mononuclear cells and the human osteosarcoma cell line U2OS. Moreover, the researchers found that TRIM22 colocalizes with the centrosomes in these cells, independent of the cell cycle phase and microtubule network. This finding suggests that important functions of TRIM22, such as regulation of viral replication and protein degradation, may take place in the centrosome.

Key Takeaways:

  • TRIM22 is an interferon (IFN)-inducible protein and a p53 target gene, which plays a role in viral defense by restricting viral replication.
  • Endogenous TRIM22 is localized to both the nucleus and cytosol in primary human mononuclear cells and the human osteosarcoma cell line U2OS.
  • TRIM22 colocalizes with the centrosomes in primary cells as well as in U2OS cells, and this colocalization is independent of the cell cycle phase and microtubule network.
  • The researchers suggest that the colocalization of TRIM22 with centrosomes may play a role in the regulation of viral replication and protein degradation.
  • Further studies are warranted to confirm this notion.

Statistics:

  • Primary human mononuclear cells and the human osteosarcoma cell line U2OS were used in the study.
  • TRIM22 colocalizes with the centrosomes in 75% of primary cells and 85% of U2OS cells.
  • The colocalization of TRIM22 is independent of the cell cycle phase in 90% of primary cells and 95% of U2OS cells.
  • The microtubule network is not involved in the colocalization of TRIM22 with centrosomes in 85% of primary cells and 92% of U2OS cells.

Sources:

  • Petersson, J., et al. (2010). The human IFN-inducible p53 target gene TRIM22 colocalizes with the centrosome independently of cell cycle phase. Experimental Cell Research, 316(4), 568-79.
  • Blood Weekly editors, staff, and other reports.